Suppr超能文献

基于半胱氨酸蛋白酶抑制剂的工程化蛋白支架寡聚化机制的研究。

Studies of the oligomerisation mechanism of a cystatin-based engineered protein scaffold.

机构信息

Manchester Institute of Biotechnology and School of Chemistry, Faculty of Science and Engineering, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.

Department of Chemistry, Technical University of Denmark, Building 207, DK-2800 Kgs, Lyngby, Denmark.

出版信息

Sci Rep. 2019 Jun 21;9(1):9067. doi: 10.1038/s41598-019-45565-6.

Abstract

Engineered protein scaffolds are an alternative to monoclonal antibodies in research and drug design due to their small size, ease of production, versatility, and specificity for chosen targets. One key consideration when engineering such proteins is retaining the original scaffold structure and stability upon insertion of target-binding loops. SQT is a stefin A derived scaffold protein that was used as a model to study possible problems associated with solution behaviour of such aptamers. We used an SQT variant with AU1 and Myc insertion peptides (SQT-1C) to study the effect of peptide insertions on protein structure and oligomerisation. The X-ray structure of monomeric SQT-1C revealed a cystatin-like fold. Furthermore, we show that SQT-1C readily forms dimers and tetramers in solution. NMR revealed that these oligomers are symmetrical, with inserted loops comprising the interaction interface. Two possible mechanisms of oligomerisation are compared using molecular dynamics simulations, with domain swap oligomerisation being thermodynamically favoured. We show that retained secondary structure upon peptide insertion is not indicative of unaltered 3D structure and solution behaviour. Therefore, additional methods should be employed to comprehensively assess the consequences of peptide insertions in all aptamers, particularly as uncharacterized oligomerisation may alter binding epitope presentation and affect functional efficiency.

摘要

工程蛋白支架由于其体积小、生产容易、多功能性以及对选定靶标的特异性,成为研究和药物设计中替代单克隆抗体的一种选择。在对这些蛋白质进行工程设计时,一个关键的考虑因素是在插入靶结合环时保留原始支架结构和稳定性。SQT 是一种衍生自 Stefin A 的支架蛋白,被用作研究此类适体溶液行为相关问题的模型。我们使用带有 AU1 和 Myc 插入肽的 SQT 变体(SQT-1C)来研究肽插入对蛋白质结构和寡聚化的影响。单体 SQT-1C 的 X 射线结构揭示了一种半胱氨酸蛋白酶抑制剂样折叠。此外,我们表明 SQT-1C 很容易在溶液中形成二聚体和四聚体。NMR 显示这些寡聚体是对称的,插入的环构成相互作用界面。使用分子动力学模拟比较了两种可能的寡聚化机制,发现结构域交换寡聚化在热力学上是有利的。我们表明,肽插入后保留的二级结构并不表示未改变的 3D 结构和溶液行为。因此,应该采用其他方法全面评估所有适体中肽插入的后果,特别是因为未表征的寡聚化可能会改变结合表位的呈现方式并影响功能效率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edea/6588553/6cfd46423615/41598_2019_45565_Fig1_HTML.jpg

相似文献

1
Studies of the oligomerisation mechanism of a cystatin-based engineered protein scaffold.
Sci Rep. 2019 Jun 21;9(1):9067. doi: 10.1038/s41598-019-45565-6.
2
3
6
The three-dimensional solution structure of human stefin A.
J Mol Biol. 1995 Feb 17;246(2):331-43. doi: 10.1006/jmbi.1994.0088.
7
Crystal structure of human cystatin C stabilized against amyloid formation.
FEBS J. 2010 Apr;277(7):1726-37. doi: 10.1111/j.1742-4658.2010.07596.x. Epub 2010 Feb 19.
8
Mutational analysis of two stefin A epitopes.
Biol Chem. 1999 Jun;380(6):723-6. doi: 10.1515/BC.1999.091.
9
Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications.
Protein Eng Des Sel. 2014 May;27(5):145-55. doi: 10.1093/protein/gzu007. Epub 2014 Mar 25.
10
Domain swapping in N-truncated human cystatin C.
J Mol Biol. 2004 Jul 30;341(1):151-60. doi: 10.1016/j.jmb.2004.06.013.

引用本文的文献

本文引用的文献

1
Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancer.
N Biotechnol. 2018 Oct 25;45:28-35. doi: 10.1016/j.nbt.2018.02.008. Epub 2018 Feb 21.
3
Alternative reagents to antibodies in imaging applications.
Biophys Rev. 2017 Aug;9(4):299-308. doi: 10.1007/s12551-017-0278-2. Epub 2017 Jul 27.
4
Insights into the mechanism of cystatin C oligomer and amyloid formation and its interaction with β-amyloid.
J Biol Chem. 2017 Jul 7;292(27):11485-11498. doi: 10.1074/jbc.M117.786558. Epub 2017 May 9.
5
Proline Residues as Switches in Conformational Changes Leading to Amyloid Fibril Formation.
Int J Mol Sci. 2017 Mar 7;18(3):549. doi: 10.3390/ijms18030549.
6
Recent advances in (therapeutic protein) drug development.
F1000Res. 2017 Feb 7;6:113. doi: 10.12688/f1000research.9970.1. eCollection 2017.
7
Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.
Drug Dev Ind Pharm. 2017 Apr;43(4):519-530. doi: 10.1080/03639045.2017.1278768. Epub 2017 Jan 22.
8
Human cystatin C monomer, dimer, oligomer, and amyloid structures are related to health and disease.
FEBS Lett. 2016 Dec;590(23):4192-4201. doi: 10.1002/1873-3468.12463. Epub 2016 Nov 2.
9
Stapled peptide design: principles and roles of computation.
Drug Discov Today. 2016 Oct;21(10):1642-1653. doi: 10.1016/j.drudis.2016.06.012. Epub 2016 Jun 18.
10
Review stapling peptides using cysteine crosslinking.
Biopolymers. 2016 Nov;106(6):843-852. doi: 10.1002/bip.22877.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验